ð é«åžçç
ð äžé éé»
HFrEF â 4 Pillars (Quadruple Therapy 2024)
1. ARNI / ACEi / ARB
- ARNI (sacubitril/valsartan) â preferred (PARADIGM-HF, PIONEER-HF, TRANSITION trials)
- ACEi (lisinopril, enalapril, ramipril) â alternative
- ARB (losartan, candesartan) â if ACEi intolerance
- Mortality benefit + symptom improvement
2. β-Blocker
- Carvedilol, metoprolol succinate (extended-release), bisoprolol â evidence-based
- Mortality benefit
- Start low + titrate up
3. MRA (Mineralocorticoid Receptor Antagonist)
- Spironolactone, eplerenone
- Mortality benefit
- Monitor K+ + renal function
- Hyperkalemia risk (especially with ACEi/ARB)
4. SGLT2i (Sodium-Glucose Cotransporter 2 Inhibitor)
- Dapagliflozin, empagliflozin (DAPA-HF, EMPEROR-Reduced)
- Mortality + HF hospitalization reduction
- Benefit independent of diabetes
- Add to other 3 pillars
HFrEF â Additional Therapies
Diuretics
- Loop diuretics (furosemide, torsemide, bumetanide) â symptomatic relief; no mortality benefit
- Titrate to euvolemia + symptom control
Ivabradine
- For sinus rhythm + HR ⥠70 bpm on β-blocker
- If channel inhibitor (sinus node)
- SHIFT trial â symptom + outcome improvement
Hydralazine + Nitrates (BiDil)
- African American + HFrEF NYHA III-IV (A-HeFT trial)
- Especially when ACEi/ARB not tolerated
- Less evidence in other populations
Digoxin
- Symptomatic improvement in HFrEF
- Reduces hospitalization (no mortality benefit)
- Especially with AF (rate control)
- Monitor levels (toxicity: arrhythmia, GI, visual)
IV Iron (Ferric Carboxymaltose, Ferric Derisomaltose)
- For symptomatic HFrEF + iron deficiency (ferritin < 100 ng/mL or 100-300 with TSAT < 20%)
- Improves exercise capacity + symptoms + reduces hospitalization (CONFIRM-HF, AFFIRM-AHF)
HFrEF â Devices
Implantable Cardioverter Defibrillator (ICD)
- HFrEF EF †35% + NYHA II-III on optimal GDMT ⥠3 months
- Mortality reduction (MADIT-II, SCD-HeFT)
- Primary prevention of sudden cardiac death
- Wearable cardioverter defibrillator (LifeVest) as bridge
Cardiac Resynchronization Therapy (CRT)
- HFrEF + EF †35% + LBBB + QRS > 130 ms + NYHA II-III on optimal GDMT
- Symptom improvement + mortality reduction (CARE-HF, MADIT-CRT)
- Bi-ventricular pacing
- Especially benefits LBBB > non-LBBB
HFrEF Advanced Therapies
LVAD (Left Ventricular Assist Device)
- Bridge to transplant or destination therapy
- HeartMate 3 (current dominant device)
- Continuous-flow rotary pumps
- Improves survival + quality of life in advanced HF
- Complications: bleeding, thrombosis, infection, RV failure
Heart Transplantation
- Refractory advanced HF (NYHA IIIb-IV despite optimal therapy)
- Limited by donor availability
- 1-year survival ~ 90%; 5-year ~ 75%
- Complications: rejection, infection, malignancy, CAV (cardiac allograft vasculopathy)
Palliative Care
- For end-stage HF when transplant/LVAD not options
- Symptom management
- Goals of care discussions
- Hospice integration
HFpEF Management (2024 Update â DELIVER, EMPEROR-Preserved)
SGLT2i (Class I â 2023 ACC/AHA + 2024 ESC)
- Dapagliflozin or empagliflozin
- DELIVER + EMPEROR-Preserved trials
- Reduces HF hospitalization + CV death
- Class I recommendation for HFpEF
Diuretics
- Loop diuretics for symptomatic congestion
- No mortality benefit
Comorbidity Management
- Hypertension control (< 130/80)
- AF rhythm/rate control + anticoagulation
- Obesity management (weight loss, lifestyle, bariatric surgery, GLP-1 RA)
- DM management (SGLT2i + GLP-1 RA preferred)
- CKD management
- OSA treatment (CPAP)
Emerging Therapies (2024)
- Tirzepatide (GIP/GLP-1 dual agonist) â STEP-HFpEF Phase 3 success 2024 in HFpEF + obesity
- Semaglutide (GLP-1 RA) for HFpEF + obesity (STEP-HFpEF, FLOW)
- Finerenone (non-steroidal MRA) â FINEARTS-HF trial 2024 in HFpEF + HFmrEF (modest benefit)
What Doesnât Work in HFpEF
- ACEi / ARB / β-blocker / MRA â no consistent mortality benefit in pure HFpEF (some sub-analyses show benefit)
- Spironolactone showed benefit in TOPCAT post-hoc Americas subset
Stages-Based Therapy
Stage A (At Risk)
- Risk factor modification:
- HTN control
- DM control
- Obesity management (lifestyle + GLP-1 RA + bariatric)
- OSA treatment
- Smoking cessation
- Lipid management
- Exercise + diet
Stage B (Pre-HF â Structural Heart Disease Without Symptoms)
- All of Stage A
- β-blocker for post-MI LV dysfunction
- ACEi/ARB for asymptomatic LV dysfunction
- SGLT2i for diabetic with structural heart disease
Stage C (Symptomatic HFrEF)
- Quadruple therapy (ARNI + β-blocker + MRA + SGLT2i)
- Diuretics for symptoms
- ICD + CRT as indicated
- Lifestyle + comorbidity management
Stage C (Symptomatic HFpEF)
- SGLT2i
- Diuretics for symptoms
- Comorbidity management
- GLP-1 RA + lifestyle for obesity (STEP-HFpEF)
- Tirzepatide emerging
Stage D (Advanced HF)
- Optimize medical therapy (often not tolerated)
- LVAD bridge to transplant or destination
- Heart transplantation
- Palliative care
- Hospice
Drug Titration Approach (HFrEF 2024)
- Rapid initiation + titration within 6 weeks (early benefit)
- Start all 4 pillars early (within days of diagnosis or hospitalization)
- Titrate to target doses or maximally tolerated
- Frequent follow-up (every 1-2 weeks initially)
Monitoring + Follow-Up
- Symptoms (NYHA, dyspnea, edema, weight)
- Vital signs (BP, HR)
- Labs: K+, renal function, BNP/NT-proBNP
- Adherence
- Echo (annually or with status change)
- Cardiac rehabilitation
- Smoking cessation, weight, exercise, sodium restriction
1ïžâ£ HFrEF â Quadruple Therapy Detail
ARNI (Sacubitril/Valsartan)
Mechanism
- Neprilysin inhibitor (sacubitril) â prevents degradation of natriuretic peptides + bradykinin
- ARB (valsartan) â blocks AT1 receptor
- Combined effect: natriuretic peptide augmentation + RAS blockade
Indication
- HFrEF (EF †40%) + symptomatic NYHA II-IV
- Preferred over ACEi/ARB when tolerated (PARADIGM-HF â 20% mortality reduction vs enalapril)
Dosing
- Sacubitril/valsartan 49/51 mg PO bid initially
- Titrate to 97/103 mg bid (target)
- Switching from ACEi: 36-hour washout (avoid angioedema)
- Renal + age + BP considerations
Side Effects + Contraindications
- Hypotension
- Hyperkalemia
- Renal dysfunction
- Angioedema (history of angioedema = contraindication; black box warning)
- Pregnancy contraindicated (teratogenic â both components)
Trials
- PARADIGM-HF (NEJM 2014): sacubitril/valsartan superior to enalapril in HFrEF
- PIONEER-HF: in-hospital initiation safe + effective
- TRANSITION: switching from ACEi/ARB
β-Blockers
Evidence-Based Agents (Not All β-Blockers Are Equal)
- Carvedilol (α + β1 + β2 blocker) â multiple trials
- Metoprolol succinate (extended-release) â MERIT-HF
- Bisoprolol â CIBIS-II
- Nebivolol (selective β1 with NO release) â SENIORS trial (older adults)
Indication
- All HFrEF
- Start low + titrate up to maximally tolerated or target
Side Effects
- Bradycardia, hypotension, fatigue
- Bronchospasm (caution in COPD/asthma)
- Worsening HF initially (especially with rapid initiation) â start low + go slow
MRA (Mineralocorticoid Receptor Antagonist)
Agents
- Spironolactone (RALES â NYHA III-IV; HFrEF)
- Eplerenone (EMPHASIS-HF â NYHA II-IV; selective without antiandrogen effects)
Indication
- All HFrEF on ACEi/ARB/ARNI + β-blocker
- Monitor K+ + renal function
- Avoid if K+ > 5.0 mEq/L or Cr > 2.5
Side Effects
- Hyperkalemia (especially with ACEi/ARB)
- Gynecomastia (spironolactone â antiandrogen effect)
- Renal dysfunction
SGLT2i (Sodium-Glucose Cotransporter 2 Inhibitor)
Agents
- Dapagliflozin (DAPA-HF â HFrEF; DELIVER â HFpEF)
- Empagliflozin (EMPEROR-Reduced â HFrEF; EMPEROR-Preserved â HFpEF)
Mechanism (Beyond Glycosuria)
- Diuresis (osmotic + natriuretic)
- Anti-inflammatory + anti-fibrotic
- Improves cardiac metabolism
- RV + LV unloading
Indication
- All HFrEF (regardless of diabetes)
- HFpEF (Class I 2024 ESC + 2023 ACC/AHA)
- Add to other GDMT
- Significant mortality + hospitalization reduction
Side Effects
- Euglycemic DKA (rare; especially with fasting + illness)
- Genitourinary infections (mycotic, UTI)
- Volume depletion + AKI (if on diuretic)
- Lower limb amputation (canagliflozin â older concern)
Dosing
- Dapagliflozin 10 mg PO daily
- Empagliflozin 10 mg PO daily
Loop Diuretics
Agents
- Furosemide (most common)
- Torsemide (better bioavailability, may improve outcomes â TRANSFORM-HF)
- Bumetanide
Indication
- Symptomatic relief (congestion, edema, dyspnea)
- No mortality benefit
- Titrate to euvolemia
Side Effects
- Hypokalemia, hyponatremia
- Renal dysfunction
- Ototoxicity (high-dose IV)
- Hyperuricemia, gout
Ivabradine
- For sinus rhythm + HR ⥠70 bpm despite maximal β-blocker
- If channel inhibitor (sinus node specific)
- SHIFT trial â symptom + outcome improvement
- Doesnât reduce mortality but improves QoL
Hydralazine + Nitrates (BiDil)
- African American HFrEF NYHA III-IV
- A-HeFT trial â mortality reduction
- Less consistent benefit in other populations
Digoxin
- Symptomatic improvement (especially with AF rate control)
- Reduces hospitalization (DIG trial)
- No mortality benefit
- Narrow therapeutic window
- Toxicity: arrhythmia (PVCs, atrial tachycardia with block, junctional rhythm), GI, visual (yellow halos)
- Drug interactions
IV Iron
- Ferric carboxymaltose or ferric derisomaltose
- For HFrEF + iron deficiency (ferritin < 100 or 100-300 with TSAT < 20%)
- Improves exercise capacity + symptoms + reduces hospitalization
- CONFIRM-HF, FAIR-HF, AFFIRM-AHF trials
2ïžâ£ HFpEF Management 2024
SGLT2i (Class I 2023 + 2024 Guidelines)
- Dapagliflozin or empagliflozin for HFpEF
- DELIVER + EMPEROR-Preserved trials
- HF hospitalization reduction + CV death reduction
- Class I recommendation in 2024 ESC HF guidelines
- Start regardless of EF (HFmrEF + HFpEF both)
Diuretics
- Loop diuretics for symptomatic congestion
- No mortality benefit but improve symptoms + QoL
- Titrate
Comorbidity Management Critical
- Hypertension: < 130/80; multiple agents needed
- AF: rhythm/rate control + anticoagulation (CHA2DS2-VASc)
- Obesity: weight loss, lifestyle, GLP-1 RA, bariatric
- DM: SGLT2i + GLP-1 RA preferred
- OSA: CPAP
- CKD: SGLT2i + finerenone
Emerging Therapies (2024)
Tirzepatide (STEP-HFpEF)
- GIP/GLP-1 dual agonist
- Phase 3 success in HFpEF + obesity (NEJM 2024)
- Improves symptoms, exercise capacity, weight loss
- Increasing role in HFpEF + obesity
Semaglutide (STEP-HFpEF, FLOW)
- GLP-1 RA
- Similar benefit in HFpEF + obesity
- Weight loss + symptom improvement
Finerenone (FINEARTS-HF)
- Non-steroidal MRA
- 2024 trial: modest benefit in HFpEF + HFmrEF
- Class IIa in newer guidelines
Specific Subtypes
Cardiac Amyloidosis (ATTR)
- Tafamidis (FDA 2019) â ATTR-CM
- Patisiran + Inotersen (TTR silencer RNA-based therapies) â ATTR
- Earlier diagnosis + treatment improves outcomes
HCM
- Mavacamten (myosin inhibitor) â symptomatic obstructive HCM (EXPLORER-HCM)
- β-blocker, calcium channel blocker, disopyramide
- Septal myectomy or alcohol septal ablation for refractory obstructive
Constrictive Pericarditis
What Doesnât Work in Pure HFpEF
- ACEi (PEP-CHF, CHARM-Preserved) â neutral
- ARB (CHARM-Preserved) â neutral
- β-blocker (most trials neutral)
- MRA (TOPCAT â neutral overall; benefit in Americas subset post-hoc)
- ARNI (PARAGON-HF â borderline; women + lower EF subgroup)
3ïžâ£ ICD + CRT
ICD Primary Prevention
Indication
- HFrEF EF †35% + NYHA II-III on optimal GDMT ⥠3 months
- EF †30% + NYHA I (some indications)
- Reassess EF after optimization
- Avoid first 40 days post-MI (DINAMIT trial)
Special Considerations
- HFrEF + LBBB â consider CRT-D (combined CRT + ICD)
- HCM + risk factors
- Channelopathies (LQTS, Brugada, CPVT) â see Ch 265
Subcutaneous ICD (S-ICD)
- No transvenous lead
- For young patients, vascular access issues
- Cannot pace
CRT (Cardiac Resynchronization Therapy)
Indication
- HFrEF EF †35%
- LBBB + QRS > 130 ms
- NYHA II-III on optimal GDMT
- Sinus rhythm preferred
- Class IIa for QRS 120-130 ms
- Some indications for non-LBBB
Trials
- CARE-HF (NEJM 2005)
- MADIT-CRT (NEJM 2009)
- RAFT (NEJM 2010)
- Reduce mortality + HF hospitalization + improve symptoms
Procedure
- Biventricular pacemaker
- Leads in RV + coronary sinus (LV)
- Pacing simultaneously to resynchronize
Combined CRT-D
- CRT + ICD
- For patients meeting both indications
4ïžâ£ Advanced HF
Recognition
- NYHA IIIb-IV despite optimal medical therapy
- Recurrent hospitalizations
- Intolerance to GDMT (hypotension, renal failure)
- High BNP / NT-proBNP
- Need for inotropic support
- End-organ dysfunction
- Cardiorenal syndrome
Workup
- Right heart catheterization for hemodynamics
- Cardiopulmonary exercise testing (VO2 max < 14 mL/kg/min for transplant consideration)
- Right + left heart catheterization
- Comprehensive workup for transplant / LVAD candidacy
LVAD (Left Ventricular Assist Device)
Indications
- Bridge to transplant (BTT)
- Destination therapy (DT) â patients ineligible for transplant
- Bridge to candidacy (improving to make transplant-eligible)
- Bridge to recovery (rare)
Current Devices
- HeartMate 3 (centrifugal continuous-flow; current standard)
- Older: HeartMate II (axial-flow), HeartWare (centrifugal)
Outcomes
- 1-year survival 80%+
- 2-year survival 70%+
- Quality of life significantly improved
Complications
- Bleeding (GI angiodysplasia common)
- Thrombosis
- Infection (driveline, pocket, bloodstream)
- RV failure
- Stroke
- Aortic regurgitation (late)
Heart Transplantation
Indications
- Advanced HF refractory to optimal medical therapy
- VO2 max < 14 mL/kg/min (< 12 if on β-blocker)
- Recurrent hospitalizations
- LVAD complications
Donor + Recipient Matching
- Blood type
- Size
- Sensitization status (PRA â panel reactive antibodies)
- Crossmatch
Outcomes
- 1-year survival ~ 90%
- 5-year survival ~ 75%
- 10-year survival ~ 50%
Post-Transplant Issues
- Acute rejection (cellular + antibody-mediated)
- Infection (immunosuppression â CMV, fungal, PJP)
- Malignancy (lymphoma, skin, others)
- Cardiac Allograft Vasculopathy (CAV) â accelerated CAD; surveillance with annual coronary angiogram or imaging
- Renal failure (calcineurin inhibitor toxicity)
Palliative Care
- Symptom management
- Advance care planning
- Goals of care
- Hospice referral when appropriate
- Integration with cardiology
- 2014 ACC/AHA recommendation for palliative consultation in advanced HF